Genzyme Corporation and Veracyte, Inc. Announce Global Co-Promotion Agreement to Deliver Personalized Solution for Thyroid Patients

CAMBRIDGE, Mass. & SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genzyme, a Sanofi company (EURONEXT: SAN and NYSE: SNY) and one of the world’s leading biotechnology companies, and Veracyte, Inc., a molecular diagnostics company pioneering the emerging field of molecular cytology, today announced a global co-promotion partnership to provide a comprehensive solution for thyroid patients. The arrangement will give patients worldwide increased access to an advanced personalized medicine solution for improved diagnosis of thyroid nodules, and the potential to significantly reduce the number of unnecessary thyroidectomies.